Influence of crystallizing and non-crystallizing cosolutes on trehalose crystallization during freeze-drying.
OBJECTIVE
To study the influence of crystallizing and non-crystallizing cosolutes on the crystallization behavior of trehalose in frozen solutions and to monitor the phase behavior of trehalose dihydrate and mannitol hemihydrate during drying.


METHODS
Trehalose (a lyoprotectant) and mannitol (a bulking agent) are widely used as excipients in freeze-dried formulations. Using differential scanning calorimetry (DSC) and X-ray diffractometry (XRD), the crystallization behavior of trehalose in the presence of (i) a crystallizing (mannitol), (ii) a non-crystallizing (sucrose) solute and (iii) a combination of mannitol and a model protein (lactose dehydrogenase, catalase, or lysozyme) was evaluated. By performing the entire freeze-drying cycle in the sample chamber of the XRD, the phase behavior of trehalose and mannitol were simultaneously monitored.


RESULTS
When an aqueous solution containing trehalose (4% w/v) and mannitol (2% w/v) was cooled to -40°C at 0.5°C/min, hexagonal ice was the only crystalline phase. However, upon warming the sample to the annealing temperature (-18°C), crystallization of mannitol hemihydrate was readily evident. After 3 h of annealing, the characteristic XRD peaks of trehalose dihydrate were also observed. The DSC heating curve of frozen and annealed solution showed two overlapping endotherms, attributed by XRD to the sequential melting of trehalose dihydrate-ice and mannitol hemihydrate-ice eutectics, followed by ice melting. While mannitol facilitated trehalose dihydrate crystallization, sucrose completely inhibited it. In the presence of protein (2 mg/ml), trehalose crystallization required a longer annealing time. When the freeze-drying was performed in the sample chamber of the diffractometer, drying induced the dehydration of trehalose dihydrate to amorphous anhydrate. However, the final lyophiles prepared in the laboratory lyophilizer contained trehalose dihydrate and mannitol hemihydrate.


CONCLUSIONS
Using XRD and DSC, the sequential crystallization of ice, mannitol hemihydrate, and trehalose dihydrate was observed in frozen solutions. Mannitol, by readily crystallizing as a hemihydrate, accelerated trehalose dihydrate crystallization in frozen solutions. However, by remaining amorphous, sucrose completely inhibited trehalose dihydrate crystallization. Crystallization of the lyoprotectantt in the model protein formulations might have serious implications on protein stability.
Sundaramurthi
Prakash
P
Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Suryanarayanan
Raj
R
D002152:Calorimetry, Differential Scanning; D003460:Crystallization; D005612:Freeze Drying; D014199:Trehalose / Q000737:chemistry*; D014961:X-Ray Diffraction
D014199:Trehalose
Pharm Res. 1999 Sep;16(9):1441-8
10496663
Pharm Res. 1993 Aug;10(8):1232-7
8415413
Pharm Res. 2009 Jul;26(7):1596-606
19326191
J Pharm Sci. 1995 Mar;84(3):318-23
7616371
Pharm Res. 2004 Feb;21(2):191-200
15032301
Pharm Res. 2001 Apr;18(4):474-9
11451034
J Pharm Sci. 2005 Apr;94(4):809-20
15729705
J Pharm Sci. 2004 May;93(5):1253-63
15067701
Pharm Res. 1996 Jan;13(1):146-50
8668665
Pharm Res. 2005 Nov;22(11):1978-85
16132343
J Phys Chem B. 2010 Apr 15;114(14):4915-23
20302316
Pharm Res. 2004 Jul;21(7):1167-76
15290856
Science. 1963 Sep 6;141(3584):921-3
14043338
J Pharm Sci. 2002 Apr;91(4):914-22
11948529
Pharm Res. 2001 Oct;18(10):1448-54
11697471
J Pharm Sci. 2001 Jul;90(7):872-87
11458336
J Pharm Sci. 2002 Sep;91(9):1969-79
12210044
Pharm Res. 2001 Jan;18(1):90-7
11336359
Pharm Res. 2010 Nov;27(11):2374-83
20811935
Pharm Res. 2007 Feb;24(2):370-6
17177113
Pharm Biotechnol. 2002;14:47-127
12189730
Pharm Res. 1997 Aug;14(8):969-75
9279875
PDA J Pharm Sci Technol. 1997 Mar-Apr;51(2):96-101
9146041
Acta Crystallogr B. 1970 Mar 31;26(3):290-9
5467313
Pharm Dev Technol. 2004;9(1):85-95
15000469
Pharm Res. 2004 May;21(5):867-74
15180347
J Pharm Sci. 2005 Apr;94(4):798-808
15729706
J Pharm Sci. 2003 Nov;92(11):2272-83
14603512
Pharm Res. 2007 Mar;24(3):593-604
17245648
J Pharm Sci. 1997 Nov;86(11):1198-203
9383725
J Pharm Sci. 1998 Aug;87(8):931-5
9687336